Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes

Journal of Nutritional Biochemistry

Volumn 25, Issue 3, 2014, Pages 270-280

  Shen, Wan ^a   Gaskins, H Rex ^b   McIntosh, Michael K ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Barrier function; Dietary fat; Inflammation; Microbiota; Obesity

Indexed keywords

BARRIER FUNCTION; DIETARY FAT; INFLAMMATION; MICROBIOTA; OBESITY;

CARCINOMA, HEPATOCELLULAR; CLOSTRIDIUM; DIETARY FATS; HUMANS; INFLAMMATION; INTESTINES; LIVER NEOPLASMS; OBESITY;

EID: 84893613597     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.09.009     Document Type: Review

References (106)

1. Centers of Disease Control and Prevention. Atlanta: Version current 13 August 2012. Available at: Accessed January, 29, 2013. http://www.cdc.gov/obesity/data/trends.html.
2. World Health Organization. Obesity and Overweight. Version current March 2013. Available at: Accessed June 29, 2013. http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
3. Centers of Disease Control and Prevention. Atlanta: Version current 28 March 2013. Available at: Accessed June 29, 2013. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
4. Cañete R., Gil-Campos M., Aguilera C.M., Gil A. Development of insulin resistance and its relation to diet in the obese child. Eur J Nutr 2007, 46:181-187.
5. Hotamisligil G. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
6. Inman B., Hanley A.J., Harris S.B., Kwan J., Fantus I.G. Circulating tumor necrosis factor-alpha concentrations in native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999, 84:272-280.
7. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spielgelman B.M. Increased adipose expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995, 95:2409-2415.
8. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., Kern P.A. The expression of TNF alpha by human muscle cells. Relationship to insulin resistance. J Clin Invest 1996, 97:1111-1116.
9. Steinberg G.R., Michell B.J., Van Denderen B.J., Watt M.J., Carey A.L., Fam B.C., et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab. 2006, 4:465-474.
10. Backhed F., Ding H., Wang T., Hooper L., Hoh G., Nagy A., Semenkovich C., Gordon J. The gut microbiota as an environmental factor that regulates fat storage. Proc Nat Acad Sci. 2004, 101:15718-15723.
11. Ley R., Backhed F., Turnbaugh P., Klein S., Gordon J. Human gut microbes associated with obesity. Nature. 2005, 444:1022-1023.
12. Turnbaugh P., Backhed F., Fultion L., Gordon J. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3:213-223.
13. De-Wit N., Derrien M., Boshch-Vermeulen H., Oosterink E., Keshtkar S., Duval C., et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastro Liver Physiol. 2012, 303:G589-G599.
14. Turnbaugh P., Ley R., Mahowald M., Magrini V., Mardis E., Gordon J. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006, 444:1027-1031.
15. Ley R., Backhed F., Turnbaugh P., Klein S., Gordon J. Human gut microbes associated with obesity. Nature. 2006, 444:1022-1023.
16. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007, 56:1761-1772.
17. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A., Delzenne N., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008, 57:1470-1481.
18. Caesar R., Reigstad C., Backhed H., Reinhardt C., Ketonen M., Ostergren Lunden G., et al. Gut-derived lipopolysaccharide augments adipose tissue macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gastroenterology. 2012, 61:1701-1707.
19. Amar J., Burcelin R., Ruidavets J., Cani P., Fauvel J., Alessi M., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008, 87:1219-1223.
20. Erridge C., Attina T., Spickett C., Webb D. A high fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007, 86:1286-1292.
21. Ding S, Chi M, Scull M, Rigby R, Schwerbrock N, Magness S, et al. High fat diet: bacterial interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mice. PLOS One. 2010;5:e12191- http://dx.doi.org/10.1371/journal.pone.0012191.
22. Delzenne N., Cani P. Gut microbiota and pathogenesis of insulin resistance. Curr Diab Rep. 2011, 11:154-159.
23. Backhed F., Manchester J., Semenkovich C., Gordon J. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Nat Acad Sci. 2007, 104:979-984.
24. Rabot S., Membrez M., Bruneau A., Gerard P., Harach T., Moser M., et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010, 24:4948-4959.
25. Tilg H., Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011, 121:2126-2132.
26. Tremaroli V., Backhed F. Functional interaction between the gut microbiota and host metabolism. Nature. 2012, 489:242-249.
27. Scott K., Gratz S., Sheridan P., Flint H., Duncan S. The influence of diet on the gut microbiota. Pharmacol Res. 2013, 69:52-60.
28. Cani P., Neyrinck A., Fava F., Knauf C., Burcelin R., Tuohy K., et al. Selective increases in bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxemia. Diabetologie. 2007, 50:2374-2383.
29. Everard A., Lazarevic V., Derrien M., Girard M., Muccioli G., Neyrinck A., et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 2011, 60:2775-2786.
30. Neyrinck A, Possemiers S, Druart C, van de Wiele T, de Backer F, Cani P. Prebiotic effects of wheat Arabinoxylan related to the increase in bifidobacteria, roseburia, and bacteroides/prevotella in diet-induced obese mice. PLOS One. 2011;6(6):e20944. Doi: doi: 10.1371/journal.pone.0020944.
31. Neyrinck A., Possemiers S., Verstraete W., de Backer F., Cani P., Delzenne N. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem. 2012, 23:51-59.
32. Neyrinck A., van Hee V., Piront N., de Backer F., Toussaint O., Cani P., et al. Wheat-derived arabionoxylan oligiosaccharides with prebiotic effect increase satietogenic peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes. 2012, 2:e28. 10.1038/nutd.2011.24.
33. Dewulf E., Cani P., Neyrinck A., Possemiers S., Van Holle A., Muccioli G., et al. Inulin-type fuctans with prebiotic properties counteract GPR43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat-fed mice. J Nutr Biochem. 2011, 22:712-722.
34. Everard A., Geurts L., Van Roye M., Delzenne N.M., Cani P. Tetrahydro iso-alpha acids from hops improve glucose homeostasis and reduce body weight gain and metabolic endotoxemia in high-fat diet-fed mice. PLOS One 2012, 7(3):e33858. 10.1371/journal.pone.0033858.
35. Neyrinck A., Van Hee V., Bindels L., Possemiers S., de Backer F., Cani P., et al. Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolemia in high-fat-induced obese mice: potential implication of the gut microbiota. Br J Nutr 2013, 109:802-809.
36. Delzenne N., Neyrinck A., Backhed F., Cani P. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrin 2011, 7:639-646.
37. Kim M., Kang S., Park J., Yanagisawa M., Kim C. Short chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 2013, 145:396-406.
38. Miyoshi M., Sakaki H., Usami M., Iizuka N., Shuno K., Aoyama M., et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induce liver injury. Clin Nutr. 2011, 30:252-258.
39. Ohira H., Fujkioko Y., Katagiri C., Mamoto R., Aoyama-Ishikawa M., Amoko K., et al. Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages. J Atheroscler Thromb 2013, 20(5):425-442.
40. Korecka A., de Wouters T., Cultrone A., Lapaque N., Pettersson S., Dore J., et al. ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways. Am J Physiol Gastrointest Liver Physiol 2013, 304:G1025-G1037.
41. Koliwad S., Gray N., Wang J.-C. Angiopoietin-like 4: a glucocorticoid-dependent gatekeeper of fatty acid flux during fasting. Adipocyte 2012, 1(3):182-187.
42. Yadav H, Lee J, Lloyd J, Walter P, Rane S. 2013. Beneficial metabolic effects of a probiotic via butryate induced GLP-1 secretion. J Biol Chem doi/10.1074/jbc.M113.452516.
43. Fleissner C., Huebel N., El-Bary M., Loh G., Klaus S., Blaut M. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr. 2010, 104:919-929.
44. Serino M., Luche El, Gres S., Baylac A., Berge M., Cenac C., et al. Metabolic adaptation to a high-fat diet is associated with a change in gut microbiota. Gut 2012, 61:543-553.
45. Lam Y, Ha C, Campbell C, Mitchell A, Dinudom A, Oscarsson J, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obesity. PLOS One.7(3):e34233:1-10.
46. Barbier de La Serre C, Ellis C, Lee J, Hartman A, Rutledge J, Raybould H. Propensity to high fat diet-induced obesity in rats is associated with changes in gut microbiota and gut inflammation. Am J Physiol Gastro Liver Physiol. 2010;299:G440-G448.
47. Hildebrandt M., Hoffman C., Sherrill-Mix S., Keilbaught S., Hamady M., Chen Y., et al. High-fat diet determines the composition of the murine microbiome independently of obesity. Gastroenterology. 2009, 137:1716-1724.
48. Everard A, Belzer C, Geurts L, Ouwerkerk J, Druart C, Bindels L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. PNAS. 2013;110(22):9066-9071. Doi/10.1073/pnas.1219451110.
49. Greenblum S., Turnbaugh P., Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shits associated with obesity and inflammatory bowel disease. Proc Nat Acad Sci. 2012, 109:594-599.
50. Ravussin Y., Koren O., Spor A., LeDuc C., Gutman R., Stombaugh J., et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity. 2011, 20:738-747.
51. Robertson BR, O'Rourke JL, Neilian BA, Vandamme P, On SL, Fox JG, et al. Mucisprilum schaedleri gen. nov. sp, nov, a spiral-shaped bacterium colonizing the mucus layer of the gastrointestinal tract of laboratory rodents. Int J Syst Evol Microbial. 2005;55:1199-1204.
52. El Homsi M., Ducroc R., Jourdan Claustre J., Gertler A G., Estienne M., et al. Leptin modulates the expression of secreted and membrane-associated mucins in colonic epithelial cells by targeting PKC, PI3K, and MAPK pathways. Am J Physiol Gastrointest Liver Physiol 2007, 293(1):G365-G373.
53. Zhang C., Zhang M., Pang X., Zhao Y., Wang L., Zhao L. Structural resilience of the gut microbiota in adult mice under high-fat dietary pertubations. ISME J. 2012, 6:1848-1857.
54. Brinkworth G., Noakes M., Clifton P., Bird A. Comparative effects of very low-carbohydrate, high fat and high-carbohydrate, low-fat weight loss diets on bowel habit and fecal short-chain fatty acids and bacterial populations. Br J Nutr. 2009, 101:1493-1502.
55. Jumpertz R., Le D., Turnbaugh P., Trinidad C., Bogardus C., Gordon J., et al. Energy-balance studies reveals associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011, 94:58-65.
56. Turnbaugh P, Ridaura V, Faith J, Rey F, Knight R, Gordon J. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1(6):6ra14. Doi: 10.1126/scitranslmed.3000322.
57. Zhang C., Zhang M., Wang S., Han R., Cao Y., Hua W., et al. Interactions between gut microbiota, host genetics, and diet relevant to development of metabolic syndromes in mice. ISME J 2010, 4:232-241.
58. Carbonero F., Benefiel A.C., Alizadeh-Ghamsari A.H., Gaskins H.R. Microbial pathways in colonic sulfur metabolism and links with health and disease. Frontiers Physiol. 2012, 3:448.
59. Levine J., Ellis C.J., Furne J.K., Springfield J., Levitt M.D. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 1998, 93:83-87.
60. Roediger W.E., Duncan A., Kapaniris O., Milard S. Reducing sulfur-compounds of the colon impair colonocyte nutrition-implications for ulcerative colitis. Gastroenterology. 1993, 104:802-809.
61. Babidge W., Millard S., Roediger W. Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis. Mol Cell Biochem. 1998, 181:117-124.
62. Den Hond E., Hiele M., Evenepoel P., Peeters M., Ghoos Y., Rutgeerts P. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology. 1998, 115:584-590.
63. Christl S.U., Eisner H.D., Dusel G., Kasper H., Scheppach W. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig Dis Sci. 1996, 41:2477-2481.
64. Chapman M.A., Grahn M.F., Boyle M.A., Hutton M., Rogers J., Williams N.S. Butyrate oxidation is impaired in the colonic mucosa of suffers of quiescent ulcerative colitis. Gut. 1994, 35:73-76.
65. Rindlon J., Kang D.-J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2008, 47:241-259.
66. Deplancke G., Gaskins H.R. Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells. FASEB J 2003, 17(10):1310-1312.
67. Devkota S., Wang Y., Musch M., Leone V., Fehlner-Peach Hl, Nadimpalli A., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10-/- mice. Nature 2012, 487:104-108.
68. USDA Center for Policy and Promotion. Diet quality of Americans in 1994-96 and 2001-02 as measured by the healthy eating index-2005. Nutrition, Insight 37. (Dec. 2007).
69. Yoshimoto S., Loo T., Atarashi K., Kanda H., Sato S., Oyadomari O., et al. Obesity-induced gut microbial metabolite promotes liver cancer throught senescence secretome. Nature 2013, 499:97-102.
70. Willemsen L.E., Koetsier M.A., Balvers M., Beermann C., Stahl B., van Tol E.A. Polyunsaturated fatty acids support epithelial barrier integrity and reduce IL-4 mediated permeability in vitro. Eur J Nutr 2008, 47(4):183-191.
71. Matsunaga H., Hokari R., Kurihara C., Okada Y., Takebayashi K., Okudaira K., et al. Omega-3 polyunsaturated fatty acids ameliorate the severity of ileitis in the senescence accelerated mice (SAM)P1/Yit mice model. Clin Exp Immunol 2009, 158(3):325-333.
72. Kono H., Fujii H., Ogiku M., Tsuchiya M., Ishii K., Hara M. Enteral diets enriched with medium-chain triglycerides and N-3 fatty acids prevent chemically induced experimental colitis in rats. Transl Res 2010, 156(5):282-291.
73. Tyagi A., Kumar U., Reddy S., Santosh V.S., Mohammed S.B., Ehtesham N.Z., et al. Attenuation of colonic inflammation by partial replacement of dietary linoleic acid with α-linolenic acid in a rat model of inflammatory bowel disease. Br J Nutr. 2012, 108:1612-1622.
74. Bassaganya-Riera J., Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006, 25(3):454-465.
75. Hassan A., Ibrahim A., Mbodji K., Coëffier M., Ziegler F., Bounoure F., et al. An α-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NFκB in rats with TNBS-induced colitis. J Nutr. 2010, 140:1714-1721.
76. Ishida T., Yoshida M., Arita M., Nishitani Y., Nishiumi S., Masuda A., et al. Resolvin E1, an endogeous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamma Bowel Dis. 2010, 16:87-95.
77. Aldridge C., Razzak A., Babcock T.A., Helton W.S., Espat N.J. Lipopolysaccharide-stimulated RAW 264.7 macrophage inducible nitric oxide synthase and nitric oxide production is decreased by an omega-3 fatty acid lipid emulsion. J Surg Res 2008, 149(2):296-302.
78. Meijerink J, Plastina P, Vincken JP, Poland M, Attya M, Balvers M, et al. The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation. British Journal of Nutrition. 2011;FirstView:1-10.
79. Weldon S.M., Mullen A.C., Loscher C.E., Hurley L.A., Roche H.M. Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 2007, 18(4):250-258.
80. Mickleborough T.D., Tecklenburg S.L., Montgomery G.S., Lindley M.R. Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting pro-inflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin Nutr 2009, 28(1):71-77.
81. Ricote M., Glass C. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007, 1771(8):926-935.
82. Pascual G., Gong Al, Ogawa S., Gamliel A., Li A.C., Perissi V., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437(7059):759-763.
83. Huang F., Wei H., Luo H., Jiang S., Peng J. EPA inhibits the inhibitor of κBα(IκBα)/NFκB/muscle RING finger 1 pathway in C2C12 myotubes in a PPARg-dependent manner. Br J Nutr 2011, 105(3):348-356.
84. Draper E., Reynolds C.M., Canavan M., Mills K.H., Loscher C.E., Roche H.M. Omega-3 fatty acids attenuate dendritic cell function via NFκB independent of PPARγ. J Nutr Biochem 2011, 22(8):784-790.
85. Wang X., Pan L., Lu J., Li N., Li J. N-3 PUFAs attenuate ischemia/reperfusion induced intestinal barrier injury by activating I-FABP-PPARg pathway. Clin Nutr 2012, 31(6):951-957.
86. Chen L., Green D. Shaping the nuclear action of NFκB. Nat Rev Mol Cell Biol. 2004, 5:392-401.
87. Hu E., Kim J., Sarraf P., Spiegleman B. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation. Science. 1996, 274:2100-2103.
88. Lo C.J., Chiu K.C., Fu M., Chu A., Helton S. Fish oil modulates macrophage P44/P42 mitogen-activated protein kinase activity induced by lipopolysaccharide. J Parenter Enteral Nutr 2000, 24(3):159-163.
89. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., Li P., Lu W.J., Watkins S.M., Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
90. Rees D., Miles E.A., Banerjee T., Wells S.J., Roynette C.E., Wahle K.W., Calder P.C. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 2006, 83(2):331-342.
91. Nieto N., Torres M.I., Rios A., Gil A. Dietary polyunsaturated fatty acids improve histological and biochemical atlerations in rats with experimental ulcerative colitis. J Nutr 2002, 132(1):11-19.
92. Aziz A.A., Cruz-Hernandez C., Plouffe L.J., Casev V., Xiao C., Nimal Ratnayake W.M. Increaseing dietary alpha-linolenic acid enhances tissue levels of long-chain n-3 PUFA when linoleic acid intake is low in hamster. Ann Nutr Metab. 2010, 57:50-58.
93. Calder P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res. 2008, 52:885-897.
94. Calder P.C. The use of n-3 polyunsaturated fatty acids as therapeutic agents for inflammatory diseases. Immunol Endocr Metab Agents Med Chem 2009, 9:45-54.
95. - intestinal intraepithelial lymphocytes. J Nutr Biochem 2008, 19:475-481.
96. Whiting C.V., Bland P.W., Tarlton J.F. Dietary n-3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis. Inflamm Bowel Dis. 2005, 11:340-349.
97. Bouwens M., van de Rest O., Dellschaft N., Bromhaar M.G., de Groot L.C., Geleijinse J.M., et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009, 90(2):415-424.
98. Hudert C.A., Weylandt K.H., Lu Y., Wang J., Hong S., Dignass A., et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci. 2006, 103:11276-11281.
99. Campos F.G., Waitzberg D.L., Habr-Gama A., Logullo A.F., Noronha I.L., Jancar S., et al. Impact of parenteral n-3 fatty acids on experimental acute colitis. Br J Nutr. 2002, 87:S83-S88.
100. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Immunology 2002, 20:495-549. 10.1146/annurev.immunol.20.100301.064816.
101. Camuesco D., Comalada M., Concha A., Nieto A., Sierra S., Xaus J., et al. Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin Nutr 2006, 25(3):466-476.
102. Camuesco D., Galvez J., Nieto A., Comalada M., Rodriguez-Cabezas M.E., Concha A., et al. Dietary oilve oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr. 2005, 135:687-694.
103. Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010, 68(5):280-289.
104. Uchiyama K., Nakamura M., Odahara S., Koido S., Katahira K., Shiraishi H., et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis 2010, 16(10):1696-1707.
105. United States Department of Agriculture. Dietary Supplements. Dietary Reference Intakes: Macronutrients. Version current 2 February 2011. Available at: Accessed May 28, 2013. http://www.iom.edu/Global/News%20Announcements//media/C5CD2DD7840544979A549EC47E56A02B.ashx.
106. National Institutes of Health. Office of Dietary Supplements. Dietary Supplement Fact Sheet: Omega-3 Fatty Acids and Health. Version current 28 Octorber 2005. Available at: Accessed May 28, 2013. http://ods.od.nih.gov/factsheets/omega3fattyacidsandhealth/.